Results 201 to 210 of about 20,678 (258)

Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. [PDF]

Pharmaceuticals (Basel)
Pirera E, Di Raimondo D, D'Anna L, Tuttolomondo A.   +3 more
europepmc   +1 more source

Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention. [PDF]

Cancers (Basel)
Laeeq T, Ahmed M, Sattar H, Zeeshan MH, Ali MB.   +4 more
europepmc   +1 more source

Prevalence and Predictors of Adverse Events Associated With Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetic Patients: A Cross-sectional Study. [PDF]

Clin Med Insights Endocrinol Diabetes
Reghunath SR, Chackochan A, Thunga G, Acharya DU, Shivashankara KN, Ravindra Prabhu A, Acharya LD.   +6 more
europepmc   +1 more source

RETRACTED: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis.

PLoS One
Hasan R, Chugaeva UY, Mohammadian M, Zamanifard S, Mohammadian-Hafshejani A.   +4 more
europepmc   +1 more source

Erratum: Efficacy and Safety of DPP-4 Inhibitors and Metformin Combinations in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis [Corrigendum]. [PDF]

Diabetes Metab Syndr Obes
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Research Progress of DPP-4 Inhibitors

Mini-Reviews in Medicinal Chemistry, 2020
Diabetes mellitus (DM) is a metabolic disease, and diabetes patients have long-term higher blood sugar levels than standard. Most people with diabetes have complications that greatly affect their standard of living. Patients with type 2 DM occupy the vast majority of all diabetes patients.
Zhi-Gang Sun
exaly   +3 more sources

Pharmacoeconomic analysis of DPP-4 inhibitors

Die Pharmazie, 2013
Dipeptidyl peptidase-4 (DPP-4) inhibitors and other incretin-related drugs have attracted attention as antidiabetic agents, but they are expensive. The Japanese government has adopted a policy of reducing healthcare costs, and medical institutions must provide medical care while considering economic efficiency.
H, Teramachi, H, Ohta, T, Tachi, M, Toyoshima, T, Mizui, C, Goto, T, Tsuchiya   +6 more
openaire   +3 more sources

Efficacy and Cardiovascular Safety of DPP-4 Inhibitors

Current Drug Safety, 2021
Abstract:: Dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins belong to the class of incretin mimetics. These drugs have been available on the market for the management of type 2 diabetes mellitus (T2DM) for over a decade. Sitagliptin, linagliptin, vildagliptin, saxagliptin and alogliptin are widely available globally, whilst anagliptin ...
Nikhila A. Subrahmanyan, Rithika M. Koshy, Koshy Jacob, Joseph M. Pappachan   +3 more
openaire   +2 more sources